Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252291 · ClinicalTrials.gov registry record · Phase 3
Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics
A Phase 3 study of Asthma, sponsored by Syntara.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT00252291: Completed Phase 3 study of Asthma, sponsored by Syntara.
NCT00252291 is a Phase 3 study of Asthma that has completed, run by Syntara. The registered enrollment target is 240 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00252291, a Phase 3 study of Asthma, has completed, sponsored by Syntara.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 3 study to determine the sensitivity and specificity of the Aridol bronchial challenge test to detect bronchial hyperresponsiveness in patients with suspected asthma. Patients with suspected asthma of either gender, aged between 6 and 50 years, with only mildly impaired lung function (FEV1 \>70%) are to be tested with three different bronchial hyperresponsiveness challenges (Aridol, exercise and methacholine), and the results compared. A clinical diagnosis will also be made at the end of the study.
Conditions Studied
Interventions
- DRUG Aridol
- DRUG Methacholine
- PROCEDURE Exercise challenge
Study Locations (1)
Colorado
- Colorado Asthma and Allergy Centers, 125 Rampart Way - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00252291 record still lists
NCT00252291 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Aridol is the first listed.
NCT00252291 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT00252291 about?
NCT00252291 is a clinical study titled "Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics". This is a Phase 3 study to determine the sensitivity and specificity of the Aridol bronchial challenge test to detect bronchial hyperresponsiveness in patients with suspected asthma. Patients with suspected asthma of either gender, aged between 6 and 50 years, with only mildly impaired lung function...
What is the current status of trial NCT00252291?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2005-11. Estimated completion is 2006-09.
What conditions does trial NCT00252291 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00252291?
The interventions under investigation include: Aridol (DRUG), Methacholine (DRUG), Exercise challenge (PROCEDURE).
Who is sponsoring clinical trial NCT00252291?
This trial is sponsored by Syntara, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00252291 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00252291's enrollment target sits among peer trials
240 140th of 374 higher than 234 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia